Overview
NICE is unable to make a recommendation on blinatumomab (Blincyto) for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia in adults because Amgen UK did not provide an evidence submission.
Last reviewed: 31 March 2021
Next review: We will review this decision if the company decides to make a submission.